Inflammation-Based Scores: A New Method for Patient-Targeted Strategies and Improved Perioperative Outcome in Cancer Patients

Table 3

Published studies about platelet-to-lymphocyte ratio (PLR).

Author	Cancer type	Study nature	Cutoff	Outcome
Bhatti et al. [93]	Pancreatic	Retrospective	<100; 100–200; >200	No correlation between PLR and OS
Smith et al. [94]	Pancreatic	Retrospective	<150; 151–300; >300	Higher PLR correlates with lower OS
Sakka et al. [95]	Periampullary	Retrospective	300	PLR > 300 associated with decreased survival
Smith et al. [96]	Periampullary	Retrospective	160	Higher PLR combined with CA19.9 predicts decreased survival
Smith et al. [97]	Pancreatic	Retrospective	150	PLR useful predictor for tumor resectability (combined with CA 19.9)
Lee et al. [55]	Gastric	Prospective	160	PLR normalization after one cycle of chemotherapy correlates with OS and PFS
He et al. [6]	Colorectal	Retrospective	<150; 151–300; >300	Higher PLR correlates with worse PFS and OS. NLR better prognostic factor than PLR
Feng et al. [7]	Esophageal	Prospective	150	PLR > 150 associated with decreased RFS and OS
Chua et al. [41]	Appendicular epithelial malignancy	Retrospective	166	PLR > 166 associated with lower OS and PFS
Carrhuters et al. [42]	Rectal	Retrospective	160	PLR > 160 associated with lower OS, DFS and TTLR
Aliostaouglu et al. [26]	Gastric	Retrospective	160	PLR < 160 associated with significantly higher survival

OS: overall survival; DFS: disease free survival; PFS: progression-free survival; RFS: relapse-free survival; TTLR: time to local recurrence.